Grants fund six studies on shared drivers of diabetes, lupus, and MS
Researchers get up to $150K each to study how autoimmunne diseases develop
Written by |
Six researchers will receive up to $150,000 each to investigate biological mechanisms that may be shared across multiple sclerosis, type 1 diabetes, and systemic lupus erythematosus. (Photo from iStock)
- New research grants are funding studies to investigate shared biological mechanisms across MS, type 1 diabetes, and lupus.
- Six researchers will each receive a Common Mechanisms in Autoimmunity Insight Award of up to $150,000.
- Identifying these shared pathways aims to accelerate the development of cross-condition therapies.
Six researchers will receive up to $150,000 each to investigate biological mechanisms that may be shared across multiple sclerosis (MS), type 1 diabetes, and systemic lupus erythematosus — the most common form of lupus.
The grants are part of the Common Mechanisms in Autoimmunity Insight Awards, which supports one-year pilot projects aimed at improving understanding of how autoimmune diseases develop and identifying potential treatment targets across conditions. The initiative was established through a joint effort by the National Multiple Sclerosis Society, Breakthrough T1D, and the Lupus Research Alliance.
Applications for next years’ funding round are now open, with a deadline of Jan. 7.
“For people living with autoimmune diseases, time matters,” Maya Bader, PhD, director of research at the Lupus Research Alliance, said in a press release from the nonprofit. “By combining resources and fostering cross-disciplinary collaboration, we are accelerating the path toward overcoming the challenges of developing cures and therapies for several diseases.”
Identifying targets across conditions could speed therapy development
Autoimmune diseases develop when the immune system mistakenly attacks the body’s own cells, tissues, or organs, causing inflammation and damage. In MS, for example, these autoimmune attacks are directed against the protective covering of nerve fibers, disrupting nerve communication and causing symptoms such as difficulty walking, fatigue, and vision problems.
Although these conditions affect different parts of the body, they may share immune mechanisms. People with one autoimmune disease also have an increased likelihood of developing another.
The Insight Awards invite innovative ideas for studying common mechanisms across autoimmune conditions. Identifying biological pathways that could be targeted across different conditions may help speed the development of therapeutic options for multiple autoimmune diseases, rather than advancing strategies for each diagnosis separately.
One of this year’s awardees is Maya Arce, PhD, of the Arc Institute in California, who will study how combinations of genetic risk changes disrupt immune signaling pathways. She will focus on CD4-positive T-cells, a type of immune cell that can become overactive in autoimmune diseases. The goal is to identify molecular targets and develop therapies better suited to each patient’s genetic makeup.
Another awardee, Ka Lung Cheung, PhD, of the Icahn School of Medicine at Mount Sinai in New York, will study a signaling pathway driven by a type of immune cell called Th17. Cheung will look at how these immune cells change their behavior and produce different inflammatory signals, a process called plasticity. His research will focus on a protein called Hdac7 and test a medication that blocks its action in models of MS, diabetes, and lupus.
Gabriela Fragiadakis, PhD, of the University of California, San Francisco, will analyze data from more than 1 million individual immune cells. Fragiadakis aims to identify shared patterns in how these immune cells behave and which genes they activate across different autoimmune diseases. By grouping autoimmune diseases according to common biological features, researchers may be able to identify therapies that work across multiple autoimmune diseases.
The selected projects represent some of the most promising and rigorous research in the field today, with implications that reach across many autoimmune diseases.
Jill Norris, PhD, of the University of Colorado, will study how exposure to environmental chemicals contributes to the development of autoimmune diseases in people at risk. These include PFAS (long-lasting chemicals used in some consumer and industrial products), phenols (chemicals found in various products), and phthalates (chemicals used to make plastics more flexible). The goal is to identify environmental factors that contribute to disease risk and may represent opportunities for prevention.
For Thomas Pieber, MD, of the Medical University of Graz in Austria, the focus is on the JAK/STAT pathway, a system of proteins that carries signals inside cells and helps regulate immune activity. Pieber will test approved medications called JAK inhibitors on immune cells from patients who have been diagnosed with MS, diabetes, or lupus, and identify which may work across the three autoimmune diseases.
Ingrid Kockum, PhD, of Karolinska Institutet in Sweden, will combine genetic, clinical, and lifestyle data to study shared and disease-specific causes of autoimmunity. Kockum will use advanced data analysis and artificial intelligence to help improve early disease prediction, identify prevention opportunities, and find existing medications that could be useful for new purposes.
“The selected projects represent some of the most promising and rigorous research in the field today, with implications that reach across many autoimmune diseases,” said James Quinn, PhD, director of biomedical research at the National MS Society. “We’re excited to support work that could redefine therapeutic pathways on a broader scale.”
Leave a comment
Fill in the required fields to post. Your email address will not be published.